These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Dual PPAR alpha/gamma agonists: promises and pitfalls in type 2 diabetes. Ahmed I; Furlong K; Flood J; Treat VP; Goldstein BJ Am J Ther; 2007; 14(1):49-62. PubMed ID: 17303976 [TBL] [Abstract][Full Text] [Related]
7. The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality. Stafylas PC; Sarafidis PA; Lasaridis AN Int J Cardiol; 2009 Jan; 131(3):298-304. PubMed ID: 18684530 [TBL] [Abstract][Full Text] [Related]
8. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Fogo AB Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479 [TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma agonists in kidney disease--future promise, present fears. Mao Z; Ong AC Nephron Clin Pract; 2009; 112(4):c230-41. PubMed ID: 19546582 [TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPar gamma agonism. Patel CB; De Lemos JA; Wyne KL; McGuire DK Diab Vasc Dis Res; 2006 Sep; 3(2):65-71. PubMed ID: 17058625 [TBL] [Abstract][Full Text] [Related]
11. Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action. Walcher D; Marx N Diab Vasc Dis Res; 2004 Oct; 1(2):76-81. PubMed ID: 16302645 [TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones in dermatology. Boyd AS Int J Dermatol; 2007 Jun; 46(6):557-63. PubMed ID: 17550551 [TBL] [Abstract][Full Text] [Related]
13. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Inamoto T; Shah JB; Kamat AM Urol Oncol; 2009; 27(6):585-91. PubMed ID: 19162510 [TBL] [Abstract][Full Text] [Related]
14. Measuring biomarkers to assess the therapeutic effects of PPAR agonists? Chinetti-Gbaguidi G; Staels B Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622 [TBL] [Abstract][Full Text] [Related]
16. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Gross B; Staels B Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742 [TBL] [Abstract][Full Text] [Related]
17. Rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality? Stulc T; Ceska R Med Sci Monit; 2008 Apr; 14(4):RA45-7. PubMed ID: 18376358 [TBL] [Abstract][Full Text] [Related]
18. Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications. Halabi CM; Sigmund CD Am J Cardiovasc Drugs; 2005; 5(6):389-98. PubMed ID: 16259527 [TBL] [Abstract][Full Text] [Related]
19. Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitis. Caldwell SH; Argo CK Hepatology; 2007 Aug; 46(2):285-7. PubMed ID: 17661403 [No Abstract] [Full Text] [Related]
20. Narrowing in on cardiovascular disease: the atheroprotective role of peroxisome proliferator-activated receptor gamma. Gerry JM; Pascual G Trends Cardiovasc Med; 2008 Feb; 18(2):39-44. PubMed ID: 18308193 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]